Compare URGN & LEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URGN | LEG |
|---|---|---|
| Founded | 2004 | 1883 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | N/A |
| Metric | URGN | LEG |
|---|---|---|
| Price | $21.96 | $11.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 4 |
| Target Price | ★ $28.50 | $10.50 |
| AVG Volume (30 Days) | 998.4K | ★ 2.4M |
| Earning Date | 11-06-2025 | 10-27-2025 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.61 |
| Revenue | $96,516,000.00 | ★ $4,172,899,999.00 |
| Revenue This Year | $27.96 | N/A |
| Revenue Next Year | $123.02 | N/A |
| P/E Ratio | ★ N/A | $7.19 |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $3.42 | $6.48 |
| 52 Week High | $30.00 | $12.03 |
| Indicator | URGN | LEG |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 70.95 |
| Support Level | $21.74 | $10.86 |
| Resistance Level | $30.00 | $11.54 |
| Average True Range (ATR) | 1.56 | 0.41 |
| MACD | -0.72 | 0.09 |
| Stochastic Oscillator | 3.15 | 88.45 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Leggett & Platt Inc designs and produces engineered components and products found in homes and automobiles. It operates its business through three segments namely Bedding Products, Specialized Products, and Furniture, Flooring, and Textile Products. It generates the majority of its revenue from Bedding Products. Serving a broad suite of customers around the world, Leggett & Platt's products include bedding components, automotive seat support, and lumbar systems, specialty bedding foam and private label finished mattresses, components for home furniture, and work furniture, flooring underlayment, adjustable beds, and various other products.